# Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

> **NCT04855253** · PHASE1,PHASE2 · SUSPENDED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 30 (estimated)

## Conditions studied

- DLBCL
- Diffuse Large B Cell Lymphoma
- High-grade B-cell Lymphoma
- DLBCL Arising From Follicular Lymphoma

## Interventions

- **DRUG:** E7777
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Tisagenlecleucel
- **DRUG:** Axicabtagene Ciloleucel
- **DRUG:** Lisocabtagene Maraleucel Intravenous Suspension

## Key facts

- **NCT ID:** NCT04855253
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-06-09
- **Primary completion:** 2026-09
- **Final completion:** 2026-12
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Accrual met
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04855253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04855253, "Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04855253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*